as 05-09-2025 10:00am EST
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | ANDOVER |
Market Cap: | 2.3B | IPO Year: | 2019 |
Target Price: | $120.11 | AVG Volume (30 days): | 1.1M |
Analyst Decision: | Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 1.01 | EPS Growth: | N/A |
52 Week Low/High: | $55.00 - $177.37 | Next Earning Date: | 05-08-2025 |
Revenue: | $441,540,000 | Revenue Growth: | 82.74% |
Revenue Growth (this year): | 25.33% | Revenue Growth (next year): | 20.53% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Khayal Tamer I | TMDX | Chief Commercial Officer | Mar 3 '25 | Sell | $76.43 | 2,407 | $183,967.01 | 36,042 |
TMDX Breaking Stock News: Dive into TMDX Ticker-Specific Updates for Smart Investing
GuruFocus.com
7 hours ago
MT Newswires
7 hours ago
Zacks
15 hours ago
Zacks
17 hours ago
Associated Press Finance
18 hours ago
PR Newswire
18 hours ago
GuruFocus.com
2 days ago
Argus Research
3 days ago
The information presented on this page, "TMDX TransMedics Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.